207 related articles for article (PubMed ID: 34082851)
1. Guidance on Gene Replacement Therapy in Spinal Muscular Atrophy: A Canadian Perspective.
Oskoui M; Gonorazky H; McMillan HJ; Dowling JJ; Amin R; Gagnon C; Selby K
Can J Neurol Sci; 2022 May; 49(3):398-401. PubMed ID: 34082851
[No Abstract] [Full Text] [Related]
2. Gene replacement therapy for spinal muscular atrophy unmasking occult hepatitis C in a pediatric patient.
Lakhotia A; Turek G; Green J; Khan M
Muscle Nerve; 2022 Jan; 65(1):E2-E3. PubMed ID: 34644404
[No Abstract] [Full Text] [Related]
3. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
Mercuri E; Muntoni F; Baranello G; Masson R; Boespflug-Tanguy O; Bruno C; Corti S; Daron A; Deconinck N; Servais L; Straub V; Ouyang H; Chand D; Tauscher-Wisniewski S; Mendonca N; Lavrov A;
Lancet Neurol; 2021 Oct; 20(10):832-841. PubMed ID: 34536405
[TBL] [Abstract][Full Text] [Related]
4. Polysomnography findings and respiratory muscle function in infants with early onset spinal muscular atrophy after gene replacement as monotherapy: A prospective study.
Barrois R; Griffon L; Barnerias C; Gitiaux C; Desguerre I; Fauroux B; Khirani S
Sleep Med; 2024 Jul; 119():335-341. PubMed ID: 38749258
[TBL] [Abstract][Full Text] [Related]
5. Necrotizing Enterocolitis following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series.
Gaillard J; Gu AR; Neil Knierbein EE
J Pediatr; 2023 Sep; 260():113493. PubMed ID: 37211209
[TBL] [Abstract][Full Text] [Related]
6. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
Al-Zaidy SA; Mendell JR
Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
[TBL] [Abstract][Full Text] [Related]
7. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
McMillan HJ; Proud CM; Farrar MA; Alexander IE; Muntoni F; Servais L
Expert Opin Biol Ther; 2022 Sep; 22(9):1075-1090. PubMed ID: 35437095
[TBL] [Abstract][Full Text] [Related]
8. Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program.
Chand DH; Mitchell S; Sun R; LaMarca N; Reyna SP; Sutter T
Pediatr Neurol; 2022 Jul; 132():27-32. PubMed ID: 35605311
[TBL] [Abstract][Full Text] [Related]
9. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy.
Schwartz M; Likhite S; Meyer K
Drugs Today (Barc); 2021 Jun; 57(6):387-399. PubMed ID: 34151905
[TBL] [Abstract][Full Text] [Related]
10. Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience.
Tokatly Latzer I; Sagi L; Lavi R; Aharoni S; Bistritzer J; Noyman I; Ginsburg M; Lev-Or A; Katzenellenbogen S; Nevo Y; Fattal-Valevski A
Pediatr Neurol; 2023 Jul; 144():60-68. PubMed ID: 37149951
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: A systematic review and meta-analysis.
Yang D; Ruan Y; Chen Y
J Paediatr Child Health; 2023 Mar; 59(3):431-438. PubMed ID: 36722610
[TBL] [Abstract][Full Text] [Related]
12. Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec.
Beri N; Kapoor L; Parashar D; Mundada V
Arch Dis Child; 2023 Oct; 108(10):866-867. PubMed ID: 37553206
[No Abstract] [Full Text] [Related]
13. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
[TBL] [Abstract][Full Text] [Related]
14. Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial.
Shell RD; McGrattan KE; Hurst-Davis R; Young SD; Baranello G; Lavrov A; O'Brien E; Wallach S; LaMarca N; Reyna SP; Darras BT
Neuromuscul Disord; 2023 Aug; 33(8):670-676. PubMed ID: 37455203
[TBL] [Abstract][Full Text] [Related]
15. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.
Stevens D; Claborn MK; Gildon BL; Kessler TL; Walker C
Ann Pharmacother; 2020 Oct; 54(10):1001-1009. PubMed ID: 32204605
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for spinal muscular atrophy: hope and caution.
Goemans N
Lancet Neurol; 2021 Apr; 20(4):251-252. PubMed ID: 33743228
[No Abstract] [Full Text] [Related]
17. [Pharmacological and clinical profile of Onasemnogene Aveparvovec, the first gene therapy for spinal muscular atrophy (SMA)].
Atsumi A; Yoneda T; Tsuchida K; Kagawa Y; Tominaga S; Kawase K; Kikuchi N
Nihon Yakurigaku Zasshi; 2022; 157(1):53-61. PubMed ID: 34980814
[TBL] [Abstract][Full Text] [Related]
18. Spinal Muscular Atrophy Treatments, Newborn Screening, and the Creation of a Neurogenetics Urgency.
Butterfield RJ
Semin Pediatr Neurol; 2021 Jul; 38():100899. PubMed ID: 34183144
[TBL] [Abstract][Full Text] [Related]
19. Spinal muscular atrophy: recent advances and future prospects.
Nicole S; Diaz CC; Frugier T; Melki J
Muscle Nerve; 2002 Jul; 26(1):4-13. PubMed ID: 12115944
[TBL] [Abstract][Full Text] [Related]
20. Monitoring spinal muscular atrophy with three-dimensional optoacoustic imaging.
Nedoschill E; Wagner AL; Danko V; Buehler A; Raming R; Jüngert J; Neurath MF; Waldner MJ; Rother U; Woelfle J; Trollmann R; Knieling F; Regensburger AP
Med; 2024 May; 5(5):469-478.e3. PubMed ID: 38531362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
